↓ Skip to main content

Alzheimer Disease

Overview of attention for book
Cover of 'Alzheimer Disease'

Table of Contents

  1. Altmetric Badge
    Book Overview
  2. Altmetric Badge
    Chapter 1 Criteria for the Clinical Diagnosis of Alzheimer’s Disease: Transcultural Aspects
  3. Altmetric Badge
    Chapter 2 Clinical and Neuropathological Findings from CERAD
  4. Altmetric Badge
    Chapter 3 Differentiating Alzheimer Disease and Vascular Dementia: Reframing the Question
  5. Altmetric Badge
    Chapter 4 Basis of Structural Alzheimer Disease and Some Pathogenic Concepts
  6. Altmetric Badge
    Chapter 5 Regional Distribution of Neuropathological Changes in Alzheimer’s Disease
  7. Altmetric Badge
    Chapter 6 Alzheimer Neurofibrillary Degeneration: A Feasible and Key Target for Therapeutics
  8. Altmetric Badge
    Chapter 7 Diabetes and Dementia: A Retrospective Neuropathologic Study of Old Diabetics Compared to Non-Diabetic Controls
  9. Altmetric Badge
    Chapter 8 Isoform-Specific Metabolism of Apolipoprotein E: Implications for Alzheimer ’s Disease
  10. Altmetric Badge
    Chapter 9 Apolipoprotein E4 and Cholinergic Activity in Alzheimer’s Disease
  11. Altmetric Badge
    Chapter 10 A New Focus on Cytoskeletal Therapy in Alzheimer’s Disease
  12. Altmetric Badge
    Chapter 11 Novel Cathepsin D Inhibitors Prevent the β-Secretase-Derived Intracellular Formation of a 12 kDa Potentially Amyloidogenic Product in Human Cells
  13. Altmetric Badge
    Chapter 12 Cellular and Test Tube Models of Amyloid-βFormation
  14. Altmetric Badge
    Chapter 13 Effects of β-Amyloid (1–40) Peptide Injection in the Nucleus Basalis
  15. Altmetric Badge
    Chapter 14 ß-Amyloid Precursor Protein — Role in Cognitive Brain Function?
  16. Altmetric Badge
    Chapter 15 Peptides Inhibitor of Amyloidogenesis in Alzheimer’s Disease
  17. Altmetric Badge
    Chapter 16 Apoptosis and Alzheimer’s Disease: A Self-Assembly and the Initiation of Apoptosis by Plasma Membrane Receptor Cross-Linking
  18. Altmetric Badge
    Chapter 17 NMDA Receptor Dysfunction in Alzheimer’s Disease
  19. Altmetric Badge
    Chapter 18 Role of Neuron-Glia Interactions in Brain Energy Metabolism: Implications for Neurodegenerative Disorders
  20. Altmetric Badge
    Chapter 19 Neurotrophins, Growth Factors and Mimetic Agents as Neuroprotectors in the Treatment of Alzheimer’s Disease
  21. Altmetric Badge
    Chapter 20 Cortical Synaptogenesis and Behavioural Consequences in CNS Lesioned Animals Receiving Neurotrophic Factor Therapy
  22. Altmetric Badge
    Chapter 21 APP Knockout and APP Over-Expression in Transgenic Mice
  23. Altmetric Badge
    Chapter 22 Alpha2c-Adrenoceptor Overexpressing Mice as a Model to Study Cognitive Functions of Alpha2-Adrenoceptors
  24. Altmetric Badge
    Chapter 23 β-App-751 Transgenic Mice: Deficits in Learning and Memory
  25. Altmetric Badge
    Chapter 24 Central and Peripheral Consequences of Cholinergic Imbalance in Alzheimer’s Disease
  26. Altmetric Badge
    Chapter 25 The Anatomy of Monoaminergic-Cholinergic Interactions in the Primate Basal Forebrain
  27. Altmetric Badge
    Chapter 26 Pharmacological Induction of Cholinergic Hypofunction as a Tool for Evaluating Cholinergic Therapies
  28. Altmetric Badge
    Chapter 27 Rational Design of New Acetylcholinesterase Inhibitors
  29. Altmetric Badge
    Chapter 28 Advances in Understanding Cholinergic Brain Neurons: Implications in the use of Citicoline (CDP-Choline) to Treat Stroke
  30. Altmetric Badge
    Chapter 29 Cholinesterase Inhibitors Do More than Inhibit Cholinesterase
  31. Altmetric Badge
    Chapter 30 Long-Term Tacrine Treatment: Effect on Nursing Home Placement and Mortality
  32. Altmetric Badge
    Chapter 31 Cholinesterase Inhibitors: An Overview of their Mechanisms of Action
  33. Altmetric Badge
    Chapter 32 Preclinical Pharmacology of Metrifonate: A Promise for Alzheimer Therapy
  34. Altmetric Badge
    Chapter 33 Eptastigmine: A Cholinergic Approach to the Treatment of Alzheimer’s Disease
  35. Altmetric Badge
    Chapter 34 Phenserine: A Selective, Long-Acting and Brain-Directed Acetylcholinesterase Inhibitor Affecting Cognition and β-APP Processing
  36. Altmetric Badge
    Chapter 35 An Overview of the Development of SDZ ENA 713, A Brain Selective Cholinesterase Inhibitor
  37. Altmetric Badge
    Chapter 36 Preclinical and Clinical Progress with Huperzine A: A Novel Acetylcholinesterase Inhibitor
  38. Altmetric Badge
    Chapter 37 P11467: An Orally-Active Acetylcholinesterase Inhibitor and α 2 -Adrenoceptor Antagonist for Alzheimer’s Disease
  39. Altmetric Badge
    Chapter 38 Cholinesterase Inhibitors as Therapy in Alzheimer’s Disease: Benefit to Risk Considerations in Clinical Application
  40. Altmetric Badge
    Chapter 39 Molecular Histochemistry of Nicotinic Receptors in Human Brain
  41. Altmetric Badge
    Chapter 40 The Nicotinic Cholinergic System and ß-Amyloidosis
  42. Altmetric Badge
    Chapter 41 RJR-2403: A CNS-Selective Nicotinic Agonist with Therapeutic Potential
  43. Altmetric Badge
    Chapter 42 ABT-089: An Orally Effective Cholinergic Channel Modulator (ChCM) with Cognitive Enhancement and Neuroprotective Action
  44. Altmetric Badge
    Chapter 43 Biochemistry, Pharmacodynamics and Pharmacokinetics of CI-1002, A Combined Anticholinesterase and Muscarinic Antagonist
  45. Altmetric Badge
    Chapter 44 Muscarinic Partial Agonists in the Symptomatic Treatment of Alzheimer’s Disease
  46. Altmetric Badge
    Chapter 45 Safety and Clinical Efficacy of S12024 in Patients with Mild to Moderate Alzheimer’s Disease
  47. Altmetric Badge
    Chapter 46 Pharmacological Characterization of PD151832, an M1 Muscarinic Receptor Agonist
  48. Altmetric Badge
    Chapter 47 Novel M1 Agonists: From Symptomatic Treatment Towards Delaying the Progression of Alzheimer’s Disease
  49. Altmetric Badge
    Chapter 48 Free Radical Scavengers Block the Actions of β-Amyloid on Neurons in Tissue Culture
  50. Altmetric Badge
    Chapter 49 Therapeutic Strategies in Alzheimer’s Disease
  51. Altmetric Badge
    Chapter 50 New Synthetic Bioantioxidants — Acetylcholinesterase (AChE) Inhibitors
  52. Altmetric Badge
    Chapter 51 Rationale to Treat Alzheimer’s Disease with Selegiline — Can We Prevent the Progression of the Disease?
  53. Altmetric Badge
    Chapter 52 Inflammatory Processes — Anti-Inflammatory Therapy
  54. Altmetric Badge
    Chapter 53 Propentofylline — Preclinical Data
  55. Altmetric Badge
    Chapter 54 Propentofylline (HWA 285): a Subgroup Analysis of Phase III Clinical Studies in Alzheimer’s Disease and Vascular Dementia
  56. Altmetric Badge
    Chapter 55 Anapsos: New Therapeutic Strategies for Neurodegeneration and Brain Aging with Neuroimmunotrophic Factors
  57. Altmetric Badge
    Chapter 56 Clinical Trials to Prevent Alzheimer’s Disease in a Population At-Risk
  58. Altmetric Badge
    Chapter 57 Effects on Decline or Deterioration
  59. Altmetric Badge
    Chapter 58 The Bridging Study: Optimizing the Dose for Phase II/III
  60. Altmetric Badge
    Chapter 59 Assessment of Therapeutic Strategies for Slowing Progression of Alzheimer’s Disease
  61. Altmetric Badge
    Chapter 60 Potential for Progress in the Therapeutics of Alzheimer’s Disease; Unanswered Questions
  62. Altmetric Badge
    Chapter 61 The Alzheimer’s Disease Assessment Scale: Modifications That Can Enhance its Use in Future Clinical Trials
  63. Altmetric Badge
    Chapter 62 An Item Pool to Assess Activities of Daily Living in Alzheimer’s Disease
  64. Altmetric Badge
    Chapter 63 Severe Impairment Battery: A Potential Measure for AD Clinical Trials
  65. Altmetric Badge
    Chapter 64 Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)
  66. Altmetric Badge
    Chapter 65 Advantages of the “Time-Index” Method for Measurement of Alzheimer Dementia: Assessment of Metrifonate Benefit
  67. Altmetric Badge
    Chapter 66 Pet-Studies Using 11C-TZTP Derivatives for the Visualization of Muscarinic Receptors in the Human Brain
  68. Altmetric Badge
    Chapter 67 Pet Imaging of Nicotinic Receptors in Alzheimer’s Disease — Implication with Diagnosis and Drug Treatment
  69. Altmetric Badge
    Chapter 68 Cerebral Spect Imaging: Advances in Radio Pharmaceuticals and Quantitative Analysis
  70. Altmetric Badge
    Chapter 69 In Vivo Imaging of Anticholinesterase Drugs Used in Alzheimer’s Disease
  71. Altmetric Badge
    Chapter 70 Spect Scan and Efficacy of Therapy in Alzheimer’s Disease
  72. Altmetric Badge
    Chapter 71 MRI and Cognitive Markers of Progression and Risk of Alzheimer Disease
  73. Altmetric Badge
    Chapter 72 Brain Mapping and Transcranial Doppler Ultrasonography in Alzheimer Disease Drug Monitoring
  74. Altmetric Badge
    Chapter 73 Apoe Genotype and MRI volumetry: Implication for Therapy
  75. Altmetric Badge
    Chapter 74 Group Psychotherapy
  76. Altmetric Badge
    Chapter 75 Non Cognitive Symptoms in Alzheimer’s Disease
  77. Altmetric Badge
    Chapter 76 Depression and Alzheimer’s Disease
  78. Altmetric Badge
    Chapter 77 Psychomotor Therapy and Alzheimer’s Disease
  79. Altmetric Badge
    Chapter 78 Behavioral Techniques for Treatment of Patients with Alzheimer’s Disease
  80. Altmetric Badge
    Chapter 79 Treatment of Psychosocial Disturbances
  81. Altmetric Badge
    Chapter 80 Serotoninergic Symptomatology in Dementia
  82. Altmetric Badge
    Chapter 81 Informed Consent and Alzheimer Disease Research: Institutional Review Board Policies and Practices
  83. Altmetric Badge
    Chapter 82 Legal Issues in Alzheimer Disease Research in France
  84. Altmetric Badge
    Chapter 83 Ethical Problems in Therapeutic Research in Alzheimer’s Disease Patients
  85. Altmetric Badge
    Chapter 84 Making Consent Work in Alzheimer Disease Research
  86. Altmetric Badge
    Chapter 85 Industry Perspectives on the Marketing of Anti-Alzheimer Disease Therapy
  87. Altmetric Badge
    Chapter 86 Codem: A Longitudinal Study on Alzheimer Disease Costs
  88. Altmetric Badge
    Chapter 87 Health Economic Aspects of Alzheimer’s Disease and the Implications for Drug Development and Pricing
  89. Altmetric Badge
    Chapter 88 International Working Group for the Harmonization of Dementia Drug Guidelines: A Progress Report
  90. Altmetric Badge
    Chapter 89 Developing Safe and Effective Antidementia Drugs
  91. Altmetric Badge
    Chapter 90 A Japanese Perspective on the Work of the International Group on Harmonization of Drug Guidelines
  92. Altmetric Badge
    Chapter 91 The Ronald and Nancy Reagan Research Institute of the Alzheimer’s Association
Overall attention for this book and its chapters
Altmetric Badge

Mentioned by

news
2 news outlets

Readers on

mendeley
1 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Alzheimer Disease
Published by
Birkhäuser Boston, December 2012
DOI 10.1007/978-1-4612-4116-4
ISBNs
978-1-4612-8660-8, 978-1-4612-4116-4
Editors

Becker, Robert E., Giacobini, Ezio, Barton, Joyce M., Brown, Mona

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 1 Mendeley reader of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 1 100%

Demographic breakdown

Readers by professional status Count As %
Professor > Associate Professor 1 100%
Readers by discipline Count As %
Computer Science 1 100%